Raymond James Financial Services Advisors Inc. Has $24.01 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Raymond James Financial Services Advisors Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 18.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 296,321 shares of the biopharmaceutical company’s stock after purchasing an additional 45,272 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Gilead Sciences were worth $24,005,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of GILD. PCA Investment Advisory Services Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $25,000. OFI Invest Asset Management acquired a new position in Gilead Sciences during the third quarter worth $26,000. Tompkins Financial Corp lifted its stake in shares of Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares in the last quarter. Union Savings Bank bought a new stake in shares of Gilead Sciences during the second quarter worth about $29,000. Finally, Fortitude Family Office LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter worth about $29,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on GILD shares. Mizuho decreased their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Oppenheimer reduced their price objective on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, February 12th. Finally, Wells Fargo & Company lowered their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and an average target price of $85.36.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the transaction, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the sale, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 8,242 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the transaction, the insider now directly owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,242 shares of company stock valued at $1,277,726. Company insiders own 0.21% of the company’s stock.

Gilead Sciences Stock Up 0.8 %

Gilead Sciences stock opened at $73.01 on Thursday. The firm has a market capitalization of $90.90 billion, a price-to-earnings ratio of 16.22, a P/E/G ratio of 0.92 and a beta of 0.18. The firm has a 50 day simple moving average of $75.38 and a 200 day simple moving average of $77.32. Gilead Sciences, Inc. has a 1-year low of $71.37 and a 1-year high of $87.86. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. During the same quarter last year, the firm posted $1.67 earnings per share. Gilead Sciences’s revenue for the quarter was down 3.7% compared to the same quarter last year. On average, analysts predict that Gilead Sciences, Inc. will post 7.07 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be paid a dividend of $0.77 per share. The ex-dividend date is Thursday, March 14th. This represents a $3.08 annualized dividend and a yield of 4.22%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is currently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.